Overview

SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea

Status:
Completed
Trial end date:
2017-02-17
Target enrollment:
Participant gender:
Summary
This is a prospective, non-interventional, open-label, multi-centre study. It will provide additional safety information of Pradaxa in Korean patients with non-valvular AF in clinical settings.
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Dabigatran